<DOC>
<DOCNO>EP-0657470</DOCNO> 
<TEXT>
<INVENTION-TITLE>
Monoclonal antibodies against in vivo glycated albumin.
</INVENTION-TITLE>
<CLASSIFICATIONS>C07K14435	C07K14765	C07K1618	C07K1618	C12N510	C12N510	C12N518	C12N518	C12N1502	C12N1502	C12P2102	C12P2102	C12P2108	C12P2108	C12R191	G01N3353	G01N3353	G01N33577	G01N33577	</CLASSIFICATIONS>
<CLASSIFICATIONS-THIRD>C07K	C07K	C07K	C07K	C12N	C12N	C12N	C12N	C12N	C12N	C12P	C12P	C12P	C12P	C12R	G01N	G01N	G01N	G01N	</CLASSIFICATIONS-THIRD>
<CLASSIFICATIONS-FOURTH>C07K14	C07K14	C07K16	C07K16	C12N5	C12N5	C12N5	C12N5	C12N15	C12N15	C12P21	C12P21	C12P21	C12P21	C12R1	G01N33	G01N33	G01N33	G01N33	</CLASSIFICATIONS-FOURTH>
<ABSTRACT>
New monoclonal antibody (MAb) against in vivo glycoslyated albumin (A) has less than 30% reactivity with non-glycosylated albumin (B) (relative to reactivity with (A)). It is produced by immunisation with (A), purified from serum by immunoaffinity chromatography and boronate chromatography; immortalisation of spleen cells from immunised animals, and cloning of those immortalised cells that contain (A)-specific antibodies in the culture supernatant. Also new are (1) the cell lines MAK 2.21.11 and 2.6.28 (DSM ACC 2052 and 2053 respectively and (2) purifcn. of (A) by immunoaffinity and boronate chromatography.
</ABSTRACT>
<APPLICANTS>
<APPLICANT-NAME>
BOEHRINGER MANNHEIM GMBH
</APPLICANT-NAME>
<APPLICANT-NAME>
BOEHRINGER MANNHEIM GMBH
</APPLICANT-NAME>
</APPLICANTS>
<INVENTORS>
<INVENTOR-NAME>
ESSIG ULRICH
</INVENTOR-NAME>
<INVENTOR-NAME>
HALLERMAYER KLAUS
</INVENTOR-NAME>
<INVENTOR-NAME>
HUEBNER-PARAJSZ CHRISTA
</INVENTOR-NAME>
<INVENTOR-NAME>
SCHLIPFENBACHER REINER
</INVENTOR-NAME>
<INVENTOR-NAME>
ESSIG, ULRICH
</INVENTOR-NAME>
<INVENTOR-NAME>
HALLERMAYER, KLAUS
</INVENTOR-NAME>
<INVENTOR-NAME>
HUEBNER-PARAJSZ, CHRISTA
</INVENTOR-NAME>
<INVENTOR-NAME>
SCHLIPFENBACHER, REINER
</INVENTOR-NAME>
</INVENTORS>
</TEXT>
</DOC>
